BioSpace News Archive

Oramed Pharmaceuticals Inc. announced today that it has enrolled over 50% of patients planned for its Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis (NASH).

Cyclo Therapeutics, Inc. today announced that N. Scott Fine, Chief Executive Officer and Sharon Hrynkow, PhD, Chief Scientific Officer and Senior Vice President for Medical Affairs of Cyclo Therapeutics, will present at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 22, 2021 at 10:45 AM ET.

Makana Therapeutics today received a $650,000 KidneyX Artificial Kidney Prize for their work to increase the supply of kidney donor organs through pig-to-human xenotransplants.

Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, Monday, September 20, 2021, 2:05 p.m. ET.

Q30 Innovations today announced the U.S. launch of the Q-Collar, the first and only FDA-cleared product that helps protect the brain from the effects associated with repetitive sub-concussive head impacts.

CohBar, Inc., a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced the appointment of Joanne Yun, Ph.D. as an independent director on the company’s Board, effective September 14, 2021.

DURECT Corporation announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc.

PsiOxus Therapeutics, Ltd. (PsiOxus), a tumor re-engineering company, today announced that they will present key safety and translational data from their first-in-human phase 1 FORTITUDE clinical study at the European Society for Medical Oncology (ESMO) Congress 2021 this week.

Nephros, Inc. today announced it has been selected to present at the 6th annual MicroCap Leadership Summit on Friday, September 24th, 2021.

AbCellera (Nasdaq: ABCL) announced today that it entered into a multi-year, multi-target research collaboration and license agreement with Moderna to leverage AbCellera’s AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna